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Abstract
Background: Persistent high-risk human papillomavirus (HPV) infection is correlated with an increased risk of developing
intraepithelial lesion or malignancy (NILM). The aims of the current study is to establish a method named BioPerfectus
Multiplex Real Time (BMRT) HPV assay for simultaneous typing and quantifying HPVs, and to evaluate it by comparison
with HPV GenoArray test and PCR-sequencing method, as well as histological status.
Methods: A total of 817 cervical specimens were evaluated by BMRT method and HPV GenoArray test, using PCR-
sequencing method as the reference standard; simultaneously, high-risk HPV-16 and -18 DNA loads were assessed in
443 specimens to investigate the correlation with infection outcomes.
Results: The overall detection coincidence rate between BMRT assay and HPV GenoArray test is 96.6 % and the Kappa
value is 0.760. In addition, the sensitivity and positive predictive value of BMRT is 98.4 % and 95.7 % compared with the
results detected by PCR-sequencing method, respectively. HPV-16 viral load has a correlation with CINs or worse lesions.
By comparing with infected women presenting NILM /cervicitis, the cutoff value for HPV-16 from patients with CINs was
0.827. With this cutoff value, 74.6 % sensitivity and 72.5 % specificity for prediction of HPV-16 infected patients with
CINI and higher CIN were achieved. High significance was obtained when comparing the infected women presenting
NILM/cervicitis with women either with CIN and cervical carcinomas (p < 0.001).
Conclusions: The BMRT assay seemed to be a good alternative approach for HR-HPV testing, due to its high level of
automation and ability to quantify HPV-16, HPV-18 and other HR-HPVs.
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Background
Development of cervical cancer is usually related to an in-
fection with human papillomavirus (HPV), especially with
any of the 12 high-risk genotypes (HR, HPV-16, −18, −31,
−33, −35, −39, −45, −51, −52, −56, −58 and −59) [1–4].
HPV-16 and HPV-18 are the most common genotypes
found in more than 70 % of cervical cancer patients, in
which HPV-16 can be detected in more than 50 % cases
[5, 6]. It seems that HPV-16 is not only more common,
but also more oncogenic [7]. Co-infection with multiple
HPV types is common [8, 9]. Studies show a tendency of
some genotypes to cluster, and some genotypes to be in-
versely associated [10–12]. The biological significance of
the individual infection in a multiple infection is however,
difficult to establish. But, there is an association between
multiple infections and increased risk of neoplasia com-
pared to single infections [8, 13, 14].
HPV viral load, as a product of the number of infected
cells and the number of virus per infected cell, is there-
fore influenced by two main factors: the extent of an
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HPV infection on the cervical surface and the level of
viral production in the infection area. Viral load has
been suggested to be a potential biomarker for cervical
intraepithelial neoplasia grade II (CINII) or higher CIN.
However, there is no consistent evidence that a one-time
measurement of viral load is a useful marker of prevalent
disease or disease progression so far [15]. The impact of
viral load change has been assessed in only a few studies
[16, 17]. An investigation in a hospitalized population of
HPV-16 positive and cytologically normal women demon-
strated that an increased HPV-16 viral load measured at
six month interval was associated with a progress of
CINII/III+ in infected women, while decreased viral load
over time was more likely to be found in women who
remained cytologically normal [17]. Changes in viral load
and the associations of the changes with disease risk may
imply the complex interaction between HPV and human
host, and potentially serve as an additional predictive
marker for the outcomes of infection.
At present, the most commercially used method for HPV
genotyping is the HPV GenoArray test (HPV GenoArray
test kit; Hybribio Ltd, Hong Kong) in China. The method
is based on reverse line blot technology (RLB), in which
the PCR products are hybridized to HPV type-specific
probes on a membrane. In our previously research, HPV
GenoArray test have been performed concerning the
prevalence and distribution of HPV genotypes in women
with cervical lesions from Liaoning Province, China, but
the main drawbacks of the assays are its high material cost
and its time-consuming performance [18]. In addition, it
is difficult to give a diagnosis for borderline cases due to
the read-outs being based on direct visualization only.
Moreover, quantifications of viral DNA in samples are un-
available by this technique. In the study, the BioPerfectus
Multiplex Real Time (BMRT) HPV assay was developed
to detect 18 HR-HPV types and 3 low risk (LR) HPV types
as well as the viral loads simultaneously, and the clinical
value of the BMRT assay was estimated in cervical speci-
mens. The purpose of the present study was to validate
the BMRT HPV assay developed for detection of 21 HPVs,
including 18 HR-HPV types of HPV-16, −18, −26, −31,
−33, −35, −39, −45, −51, −52, −53, −56, −58, −59, −66,
−68, −73, −82 and 3 LR-HPV types of HPV-6, −11, −81,
by comparing with HPV GenoArray test and to evaluate
whether the measurements of HPV-16 and −18 viral loads




Informed consent was obtained from participation in the
study and this study was approved by the ethics commit-
tee of Affiliated Shengjing Hospital of China Medical
University. Specimens were obtained from patients in
the Department of Obstetrics and Gynecology of the
hospital, who subjected for a routine diagnosis for HPV
infection, between July 2011 and November 2012. Clin-
ical data of the patients were collected. For each patient,
cervical cells were scraped from the ecto- and endocervix
with a cytobrush. The cervical specimens were placed in
the PreservCyt® LBC medium (Cytyc, Bedford, MA, USA)
and transported to the laboratory, where they were kept at
temperatures between 2 °C and 8 °C until performance
with a routine HPV GenoArray test. A total of 817 HPV
positive cervical samples detected previously, including
467 single positive samples and 350 multiple positive sam-
ples, were selected for the present study. Among them,
364 samples were HPV - 16 positive, 142 samples were
HPV - 18 positive and 311 samples were positive for other
HPV types in the routine laboratory detections. All pa-
tients in this retrospective study had liquid based cytology
test or colposcopy done at the time the cervical scrapes
were taken. The median age of the studied populations
was 39 years old (range 18–66 years old) at the time the
cervical scrapes were collected.
DNA preparations
Total cellular DNA from the residual samples was extracted
using QIAamp DNA mini kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. The concen-
tration of DNA was determined in a spectrophotometer
(DU 640, Beckman Coulter). Successful extraction of hu-
man genomic DNA was evaluated by amplifying a 258-base
pair (bp) fragment of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) gene using primers 5′-AGAAGGCTGG
GGCTCATTTG-3′ (forward) and 5′-AGGGG CCATCC
ACAGTCTTC-3′ (reverse). The PCR reactions were car-
ried out in a thermo- cycler under the following conditions:
an initial 95 °C for 9 min; 40 cycles of 94 °C for 20 s, 55 °C
for 30 s, 72 °C for 30 s; and a final extension at 72 °C for
5 min. In each PCR assay, negative and positive controls
were included. Only DNA preparations, from which the
GAPDH DNAs were successfully amplified, were used for
further analyses.
HPV GenoArray test
HPV GenoArray test was performed using HybriMax Kit
(Hybribio Limited Corp., China) according to the manufac-
turer’s instructions. Briefly, HPV specific fragments in the
DNA preparations were amplified by PCR, and genotyping
for HPVs was done by flow-through hybridization to a
gene chip as described previously [18]. The gene chip con-
tains type specific oligonucleotides immobilized on a nylon
membrane, including 13 HR-HPVs of HPV-16, −18, −31,
−33, −35, −39, −45, −51, −52, −56, −58, −59 and −68, 5
LR-HPVs of HPV-6, −11, −42, −43 and −44, and HPV-53,
−66 and -CP8304, which are popular in the Chinese
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population. The final results were determined by direct
visualization of colorimetric changes on the chip.
BMRT HPV PCR assay
In the BMRT HPV PCR assay, PCR primers and corre-
sponding TaqMan probes were designed to detect each
of the 21 most prevalent HPV types, including 18 HR-
HPV genotypes of HPV-16, −18, −26, −31, −33, −35,
−39, −45, −51, −52, −53, −56, −58, −59, −66, −68, −73
and −82, and 3 LR-HPV genotypes of HPV-6, −11 and
−81 (equivalent to CP8304). A total of eight reactions
per sample were performed simultaneously. Among
them, the reactions A, B, C, D, E, F and G were prepared
to simultaneously detect and differentiate HPV-16/-18/-
31, HPV-59/-66/-53, HPV-33/-58/-45, HPV-56/-52/-35,
HPV-68/-51/-39, HPV-73/-26/-82 and HPV-6/-11/-81,
respectively. Meanwhile, human TOP3, a single-copy
gene encoding DNA topoisomerase III, was amplified in
the reaction H as a control for determining relative
number of viral copies in a given sample [19].
PCR amplification was conducted in a total reaction vol-
ume of 20 μL, which comprised 2 μL DNA samples (up to
50 ng), 10 μL Platinum Quantitative PCR SuperMix-UDG
(Invitrogen), 10 pmol of each primer, and 1–5 pmol of
each probe (FAM™, VIC® and ROX™ dye). To prevent
reamplification of carry-over PCR products, all reactions
with Uracil-DNA-Glycosylase (UDG) were pre-incubated
at 50 °C for 5 min, followed by an initial denaturation at
95 °C for 10 min, which also inactivates UDG but activates
the DNA polymerase, and 45 cycles at 95 °C for 10 s, 58 °C
for 40 s. PCR was performed on an ABI Prism 7500 Detec-
tion System (Applied Biosystems).
Perfectus Software v1.0, which was used for genotyping
and quantitative analysis of HPV nucleic acid (Bioperfec-
tus Limited Corp., China), was applied for quantitative
analyses of HPV-16 and -18 viral loads.
Sequencing
Products of HPV L1 gene amplified from samples by
nested PCR using type-specific primers were purified
with a QIAquick PCR Purification Kit (Qiagen, Hilden,
Germany) as described by the manufacturer’s instructions,
and sequenced by Sangon Biotech Co., Ltd (Shanghai,
China). Resulting DNA sequences were compared with
the sequences of known HPV types using the basic
local alignment search tool from the NCBI website
(http://www.ncbi.nlm.nih.gov/BLAST).
Statistical analysis
Cohen’s kappa value (k) was calculated to assess the de-
gree of agreement between results achieved by BMRT
HPV PCR assay and HPV GenoArray test. Kappa values
of 0–0.2, 0.21–0.4, 0.41–0.6, 0.61–0.8, 0.81–0.99, and 1.0
indicate poor, slight, moderate, substantial, almost perfect
and perfect agreement, respectively. P values were calcu-
lated by Friedman Test. P values <0.05 were considered to
be statistically significant.
The accuracy measures of the BMRT HPV PCR assay
for detecting 21 HPVs, including sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV) and their relative 95 % confidence intervals (95 %
CI) were determined according to sequencing results of
PCR products.
Simultaneously, the accuracy measures for predicting
CINs in HPV-16 infected patients by viral loads were
stratified according to cytological and colposcopy grade.
Four patient groups were set up, in which group 1 repre-
sents negative for intraepithelial lesion or malignancy
(NILM), normal cytology and cervicitis; group 2 includes
low-grade cervical intraepithelial neoplasia histology and
observation of atypical squamous cells of undetermined
significance (ASCUS) or low-grade squamous intraepithe-
lial lesions (LSIL); group 3 is assigned for high-grade
intraepithelial neoplasia or worse (CINII+) and high grade
squamous intraepithelial lesions (HSIL); group 4 is for
cancer. In order to calculate the prediction accuracy mea-
sures of BMRT HPV PCR assay for the cytology and col-
poscopy diagnoses, only HPV-16 positive cases in the four
different thresholds were included. P values were calcu-
lated by the Kruskal-Wallis test. For statistical analysis,
the cytological and histological diagnosis was split be-
tween negative (CINI-III) and positive (cancer). Receiver
operating characteristic (ROC) curve was constructed to
find the clinical cutoff value, relative sensitivity and speci-
ficity of the BMRT HPV PCR assay. All statistical calcula-
tions were performed using the SPSS version 18.0 (SPSS
Inc, Chicago, IL, USA).
Results
Concordance rate of the BMRT HPV PCR assay with the
HPV GenoArray test
Results of infection status in both the multiple and single
HPV positive samples were organized in a 2-by-2 cross-
tabulation for each HPV type, by classifying detection re-
sults of each sample as positive or negative for both of the
BMRT HPV PCR assay and the HPV GenoArray test
(Table 1). The overall HPV positive and negative coinci-
dence rates between the two tests were 89.8 % and 97.0 %,
respectively; the total concordant coincidence was 96.6 %
yielding a kappa value of 0.760. For detections of individ-
ual HPV types, the positive coincidence rate of the two
methods was 100 % for HPV-59, HPV-68 and HPV-51.
An almost perfect agreement were obtained between the
two methods for detection of HPV-16 (k = 0.844), HPV-18
(k = 0.881) and HPV-58 (k = 0.809), respectively. And a
slight agreement was obtained for HPV-56, which showed
the lowest kappa value of 0.284. The discordant results
were mainly caused by more HPV-positive samples
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detected by the BMRT HPV PCR assay than those de-
tected by the HPV GenoArray test.
Accuracy of the BMRT HPV PCR assay compared with
sequencing results
As shown in Table 2, the sensitivity, specificity and con-
cordance rate (accuracy) of the BMRT HPV PCR assay
was 98.4 %, 99.6 % and 99.6 % by comparing with sequen-
cing results, respectively. For detection of individual HPV
types, 100 % sensitivity was achieved by the method for
detections of 13 HPV genotypes, including HPV-59, −66,
−53, −45, −56, −35, −68, −51, −39, −82, −26, −73 and −11,
and 100 % specificity and accuracy for HPV-66, −45, −82
and −73. The accuracies for detections of HPV-18, −58
and −52 by BMRT HPV PCR assay were 99.4 %, 99.4 %
and 99.1 %, respectively. However, the accuracy for detec-
tion of HPV-16, the most common HPV type, was the
lowest one (98.8 %), even though it had the highest num-
ber of samples compared to the other HPV types. Com-
pared with the sequencing results, the overall PPV and
NPV of the BMRT HPV PCR assay was 95.7 % and
99.9 %, respectively. Identical with the specificity and sen-
sitivity, the PPV of the BMRT HPV PCR assay for detec-
tions of HPV-66, −45, −82 and −73 were 100 %, and the
NPV for detections of HPV-59, −66, −53, −45, −56, −35,
68, 51, 39, 82, 26, 73 and 11 were 100 %.
Compared with sequencing results, the HPV genotyp-
ing by the BMRT HPV PCR assay showed perfect agree-
ment (k = 0.968; 95%CI, 0.961–0.975); Meanwhile, the
accuracy of the BMRT HPV PCR assay was 91.6 % (95 %
CI, 88.8–94.0, n = 467) and 90.8 % (95 % CI, 87.3–93.7,
n = 350) for samples with single and multiple infections,
respectively. For detections of individual HPV types, the
BMRT HPV PCR assay and sequencing showed almost
perfect agreement.
Analyses of discordant HPV typing results between the
BMRT HPV PCR assay and sequencing by comparing to
the historical diagnoses and infection states of the cases
The discordant HPV typing results between the BMRT
HPV PCR assay and sequencing were estimated for sin-
gle and multiple infections (Table 3). For detections of
all HPV types, total 76 cases showed discordant in
BMRT HPV PCR assay and sequencing results. Among
the 76 discordant cases, 20 cases (6 cases of single infec-
tion and 14 of multiple infections) were detected by the
sequencing but not by the BMRT HPV PCR assay. In
contrast, the other 56 cases (32 cases of single infection
and 24 of multiple infections) were identified by the
BMRT HPV PCR assay but not by the sequencing.
Among the 65 multiple infected cases, which deter-
mined by either the BMRT HPV PCR assay or sequen-
cing, 51 cases were positive for at least one additional













Total coincidence rate Kappa value
HPV16 334 32 31 420 91.5 % 92.9 % 92.3 % 0.844
HPV18 129 10 18 660 87.8 % 98.5 % 96.6 % 0.881
HPV31 23 13 2 779 92.0 % 98.4 % 98.2 % 0.745
HPV59 16 19 0 782 100.0 % 97.6 % 97.7 % 0.617
HPV66 23 10 2 782 92.0 % 98.7 % 98.5 % 0.786
HPV53 37 20 2 758 94.9 % 97.4 % 97.3 % 0.757
HPV33 30 10 7 770 81.1 % 98.7 % 97.9 % 0.768
HPV58 73 13 17 714 81.1 % 98.2 % 96.3 % 0.809
HPV45 13 7 1 796 92.9 % 99.1 % 99.0 % 0.760
HPV56 12 53 2 750 85.7 % 93.4 % 93.3 % 0.284
HPV52 44 65 6 702 88.0 % 91.5 % 91.3 % 0.513
HPV35 9 15 1 792 90.0 % 98.1 % 98.0 % 0.521
HPV68 18 31 0 768 100.0 % 96.1 % 96.2 % 0.522
HPV51 9 33 0 775 100.0 % 95.9 % 96.0 % 0.341
HPV39 14 17 1 785 93.3 % 97.9 % 97.8 % 0.599
HPV6 51 22 3 741 94.4 % 97.1 % 96.9 % 0.787
HPV11 21 13 3 780 87.5 % 98.4 % 98.0 % 0.714
HPV81 29 22 4 762 87.9 % 97.2 % 96.8 % 0.675
Total 885 405 100 13316 89.8 % 97.0 % 96.6 % 0.760
Note: aOnly types detected in both methods were included
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HPV type by the BMRT HPV PCR assay than sequen-
cing. While, among the 23 discordant cases of patients
with CINs and cancer, 19 cases were detected by the
BMRT HPV PCR assay, but only 4 cases with CINs were
detected by sequencing. These results indicate that the
BMRT HPV PCR assay may be more suitable for detect-
ing multiple infections in women with pathological le-
sions than sequencing method.
Relationship between relative DNA loads of HPV-16 or
HPV-18 and histomorphological findings of infected women
All cervical scrapes from HPV-16 and HPV-18 positive
women were taken in the course of a colposcopic examin-
ation and biopsies. Altogether, 313 HPV-16 and 130 HPV-
18 positive patients fulfilled this criterion. Among the 313
HPV-16 positive patients, 171 were NILM/cervicitis, 56
were LSIL/ASCUS/ASC-H/CINI, 63 were HSIL/CINII-III
and 23 were cervical cancer. The relationships between
relative loads of HPV-16 DNA (copies per 10,000 cells) in
corresponding cervical scrapes and the histopathological
findings of the patients were analyzed. As shown in Fig. 1,
the median viral load (lg) in patients with NILM/cervicitis,
LSIL/ASCUS/ASC-H/CINI, HSIL/CINII-III and cancer
were 3.33, 4.75, 4.99 and 5.13, respectively. Moreover,
pairwise comparisons among the four groups by Kruskal-
Wallis test showed no significant differences of viral loads
in samples between the two CIN groups, as well as be-
tween each of the two CIN groups and the cancer group.
However, highly marked differences were observed when
comparing the group presenting NILM/cervicitis to either
all grades of CIN (p < 0.001), or to cervical carcinomas
group (p < 0.001) by Mann–Whitney U test. As shown in
Fig. 2, the median viral loads (copies per 10,000 cells) in
patients with NILM/cervicitis and ASCUS/CINI-III/can-
cer were 3.33 and 4.97, respectively.
To discriminate the group of NILM and cervicitis
from CINI-III and cancer, the area under the curve
(AUC) for HPV-16 viral load was calculated for two
endpoints of CINI and greater, and of CINII and
greater. For HPV-16, the AUCs were 0.827 for CINI
and greater, and 0.786 for CINII and greater. The opti-
mal cutoff value of 16,600 copies per 10,000 cells was
selected. This value corresponds to 74.6 % sensitivity
and 72.5 % specificity for predicting CINI and greater,
to 80.2 % sensitivity and 63.0 % specificity for predict-
ing CINII and greater.
Table 2 Accuracy of the BMRT HPV PCR assay compared with sequencing from all the 817 samples






PPV NPV k 95 % CI
HPV16 361 7 3 446 99.2 % 98.5 % 1.5 % 0.8 % 98.8 % 98.1 % 99.3 % 0.975 0.960–0.991
HPV18 138 1 4 674 97.2 % 99.9 % 0.1 % 2.8 % 99.4 % 99.3 % 99.4 % 0.979 0.960–0.997
HPV31 35 1 1 780 97.2 % 99.9 % 0.1 % 2.8 % 99.8 % 97.2 % 99.9 % 0.971 0.931–1.011
HPV59 32 3 0 782 100.0 % 99.6 % 0.4 % 0.0 % 99.6 % 91.4 % 100.0 % 0.953 0.901–1.006
HPV66 33 0 0 784 100.0 % 100.0 % 0.0 % 0.0 % 100.0 % 100.0 % 100.0 % 1 ~
HPV53 54 3 0 760 100.0 % 99.6 % 0.4 % 0.0 % 99.6 % 94.7 % 100.0 % 0.971 0.938–1.004
HPV33 39 1 3 774 92.9 % 99.9 % 0.1 % 7.1 % 99.5 % 97.5 % 99.6 % 0.949 0.896–0.999
HPV58 85 1 4 727 95.5 % 99.9 % 0.1 % 4.5 % 99.4 % 98.8 % 99.5 % 0.968 0.940–0.996
HPV45 20 0 0 797 100.0 % 100.0 % 0.0 % 0.0 % 100.0 % 100.0 % 100.0 % 1 ~
HPV56 56 9 0 752 100.0 % 98.8 % 1.2 % 0.0 % 98.9 % 86.2 % 100.0 % 0.920 0.868–0.972
HPV52 104 5 2 706 98.1 % 99.3 % 0.7 % 1.9 % 99.1 % 95.4 % 99.7 % 0.963 0.935–0.990
HPV35 21 3 0 793 100.0 % 99.6 % 0.4 % 0.0 % 99.6 % 87.5 % 100.0 % 0.932 0.854–1.008
HPV68 48 1 0 768 100.0 % 99.9 % 0.1 % 0.0 % 99.9 % 98.0 % 100.0 % 0.989 0.968–1.011
HPV51 40 2 0 775 100.0 % 99.7 % 0.3 % 0.0 % 99.8 % 95.2 % 100.0 % 0.974 0.939–1.010
HPV39 30 1 0 786 100.0 % 99.9 % 0.1 % 0.0 % 99.9 % 96.8 % 100.0 % 0.983 0.950–1.016
HPV82 12 0 0 805 100.0 % 100.0 % 0.0 % 0.0 % 100.0 % 100.0 % 100.0 % 1 ~
HPV26 2 1 0 814 100.0 % 99.9 % 0.1 % 0.0 % 99.9 % 66.7 % 100.0 % 0.799 0.415–1.184
HPV73 4 0 0 813 100.0 % 100.0 % 0.0 % 0.0 % 100.0 % 100.0 % 100.0 % 1 ~
HPV6 70 3 1 743 98.6 % 99.6 % 0.4 % 1.4 % 99.5 % 95.9 % 99.9 % 0.970 0.940–0.999
HPV11 26 8 0 783 100.0 % 99.0 % 1.0 % 0.0 % 99.0 % 76.5 % 100.0 % 0.862 0.767–0.956
HPV81 45 6 2 764 95.7 % 99.2 % 0.8 % 4.3 % 99.0 % 88.2 % 99.7 % 0.913 0.854–0.973
Total 1255 56 20 15826 98.4 % 99.6 % 0.4 % 1.6 % 99.6 % 95.7 % 99.9 % 0.968 0.961–0.975
Note: aindicates the results of the BMRT HPV PCR assay, and bindicates the results of the sequencing
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Table 3 Analyses of discordant HPV typing results between the BMRT PCR assay and sequencing by comparing to the historical
diagnoses and infection states of the cases
Type Numbers of BMRT negative/sequencing positive Numbers of BMRT positive/sequencing negative
Infection states Historical diagnoses Infection states Historical diagnoses
Total (Single +multiplea) (N + CINI+ CINII-III + cancer) Total (Single + multiplea) (N + CINI+ CINII-III + cancer)
HPV16 3 (2 + 1) (3 + 0 + 0 + 0) 7 (0 + 7) (7 + 0 + 0 + 0)
HPV18 4 (0 + 4) (1 + 2 + 1 + 0) 1 (0 + 1) (1 + 0 + 0 + 0)
HPV31 1 (1 + 0) (0 + 0 + 1 + 0) 1 (0 + 1) (1 + 0 + 0 + 0)
HPV59 0 3 (1 + 2) (2 + 0 + 1 + 0)
HPV53 0 3 (0 + 3) (0 + 3 + 0 + 0)
HPV33 3 (1 + 2) (3 + 0 + 0 + 0) 1 (0 + 1) (1 + 0 + 0 + 0)
HPV58 4 (0 + 4) (4 + 0 + 0 + 0) 1 (0 + 1) (1 + 0 + 0 + 0)
HPV56 0 9 (1 + 8) (7 + 0 + 1 + 1)
HPV52 2 (1 + 1) (2 + 0 + 0 + 0) 5 (1 + 4) (3 + 0 + 1 + 1)
HPV35 0 3 (0 + 3) (0 + 0 + 2 + 1)
HPV68 0 1 (1 + 0) (1 + 0 + 0 + 0)
HPV51 0 2 (0 + 2) (1 + 0 + 1 + 0)
HPV39 0 1 (0 + 1) (1 + 0 + 0 + 0)
HPV26 0 1 (0 + 1) (1 + 0 + 0 + 0)
HPV6 1 (0 + 1) (1 + 0 + 0 + 0) 3 (0 + 3) (1 + 1 + 1 + 0)
HPV11 0 8 (1 + 7) (3 + 1 + 4 + 0)
HPV81 2 (1 + 1) (2 + 0 + 0 + 0) 6 (0 + 6) (6 + 0 + 0 + 0)
Total 20 (6 + 14) (16 + 2 + 2 + 0) 56 (5 + 51) (37 + 5 + 11 + 3)
Note: N means normal in historical diagnosis. ashow the numbers of multiple infection cases, in which additional HPV types were detected by the indicated
(Positive) method
Fig. 1 The relationship between HPV - 16 viral load and the histopathology of cervical samples
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Among 130 HPV-18 positive patients, 81 were nega-
tive in histological diagnosis (including normal, infuso-
rian and cervicitis), 27 were LSIL/ASCUS/ASC-H/CINI,
14 were HSIL/CINII-III, and 8 were cervical cancer. The
relative levels of HPV-18 DNA loads (copies per 10,000
cells) in corresponding cervical scrapes were calculated
to correlate them with the histopathological findings of
infected patients (Fig. 3). The median viral load (lg) in
patients with diagnosis of NILM/cervicitis, LSIL/ASCUS/
ASC-H/CINI, HSIL/CINII-III and cancer were 3.21, 4.84,
3.83 and 3.92, respectively. Moreover, pairwise compari-
sons among the four groups by Kruskal-Wallis test
showed highly significant difference of viral loads in sam-
ples between the group presenting NILM/cervicitis and
the group of LSIL/ASCUS/ASC-H/CINI (p < 0.001). Un-
like those of HPV16, the viral loads of HPV-18 were
less associated with progress of CINII-III. Similar to
those of HPV-16, the significant differences of HPV-18
viral loads were observed when comparing the group
presenting NILM/cervicitis to either all grades of CIN
(p < 0.001), or to cervical carcinomas group (p < 0.001)
by Mann–Whitney U test. As shown in Fig. 4, the me-
dian viral loads (copies per 10,000 cells) in patients
with NILM/cervicitis and ASCUS/CINI-III/cancer were
3.21 and 4.31, respectively.
Discussion
In clinical screening of HPV-infected women, accurate
HPV genotyping has become an important prognostic indi-
cator for monitoring persistent HPV infection, which is the
strong causality of high grade cervical intraepithelial neo-
plasia [18, 20]. In our hospital, HPV DNA is routinely de-
tected in Cervical Cancer Screening Program by the HPV
GenoArray method, which allows for genotyping of 13 HR
types, 5 LR types and 3 other types commonly found in
China [18]. However, the HPV GenoArray method does
not provide quantitative information on detected HPV
DNA. Evidence is accumulating that HPV quantification
may be useful as genotyping for patient management in
the future. In order to solve this problem, a multiplex real
time assay was designed for simultaneous genotyping and
quantification of the 18 most frequent cancer related HR-
HPV types and 3 LR-HPV types of HPV-6, −11 and −81. A
recent cross-sectional study showed that these types men-
tioned above were the predominant HPV types in women
with high-grade lesions [21].
Quantitative real-time PCR methods are considered to
be the gold standard for HPV load assessment, but these
have not been developed and validated for the genotyp-
ing and quantifying wide spectrum of carcinogenic HPV
types often encountered in cervical samples [22] . HPV
Fig. 2 Comparison of HPV - 16 viral loads between NILM/cervicitis and ASCUS/CIN I-III/cancer
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Fig. 4 Comparsion of HPV - 18 viral loads between NILM/cervicitis and ASCUS/CIN I-III/cancer
Fig. 3 The relationship between HPV - 18 viral load and the histopathology of cervical samples
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DNA viral load, usually estimated as the amount of HPV
genome copies per cell, has been variably associated with
cervical disease, and appears to have an overall specifi-
city to differentiate normal cytology from abnormal cy-
tology [23]. A novel application of the BMRT HPV PCR
assay for the HPV genotyping and quantifying is de-
scribed. The BMRT HPV PCR assay is a multiplex gene
analysis platform, offers a high sensitive, cost-effectiveness
and high throughput assay that allows the rapid and spe-
cific detection of 21 high-risk and low-risk HPV genotypes
in conjunction with BMRT genetic analysis system. Each
pair of HPV-specific primers only generated a single peak
for each HPV genotype in addition to the internal control
peak. Analyses of 817 specimens using the BMRT PCR
assay and the HPV GenoArray test demonstrated that the
BMRT PCR assay had comparable sensitivity and specifi-
city to HPV GenoArray test (Table 2). In this study, a
96.6 % of total coincidence rate and a substantial al-
most perfect agreement (k = 0.760) for genotyping 18
HPV types, which are capable detected in both the
methods, was achieved between the BMRT HPV PCR
assay and the HPV GenoArray test. The BMRT HPV
PCR assay was proved to be highly specific for typing
the 21 HPV types. This is a particular note since both
assays differ considerably in their design. The HPV
GenoArray test is based on amplification by a pair of
consensus primers in a highly conserved region of the
L1 gene and reverse hybridization to the type-specific
probes, whereas the BMRT HPV PCR assay utilizes
type-specific primers and TaqMan probes to amplify
the sequences within the L1 region. Numerous studies
have been showed that the GenoArray test is a highly
reproducible assay with an excellent clinical sensitivity
for HPV types and is thus considered to be adequate
for comparison [18, 20]. Most of the discordant results
detected by the two methods were seen in cases with
multiple infections. Generally, agreement is relatively
poor between various assays for genotyping multiple
HPV infections. A recent study, which evaluated dif-
ferent multiplex HPV PCR assays for identification of
low prevalent HPV types, revealed only moderate
inter-assay agreement in cases of single HPV infec-
tions and poor agreement in cases with multiple HPV
infections [24].
DNA sequencing is the “gold standard” method for ac-
curate HPV genotyping, in which HPV DNA is amplified
with specific primers followed by sequencing. It is desirable
to evaluate the accuracy of any HPV genotyping method on
the basis of the sequencing results [25, 26]. In this study, a
perfect agreement (k = 0.968; 95 % CI, 0.961–0.975) for
HPV genotyping between the BMRT HPV PCR assay and
sequencing was obtained. Compared with sequencing
method, the sensitivity, specificity and accuracy of the
BMRT HPV PCR assay was 98.4 %, 99.6 % and 99.6 %,
respectively. This result indicates that HPV genotype could
be successfully identified by the BMRT HPV PCR assay
with high accuracy.
The BMRT HPV PCR assay was demonstrated to have
good sensitivity, specificity, accuracy, PPV and NPV
compared to the sequencing method. Among detections
of the 21 HPV genotypes, detections of 13 HPV geno-
types by the BMRT HPV PCR assay showed 100 % sen-
sitivity and NPV value, detections of 4 HPV genotypes
showed 100 % specificity and PPV value. All HPV infec-
tions in patients with CINs and cancer were successfully
detected by the BMRT HPV PCR assay except for 2
cases of patients with CINII-III and 2 with CIN. Of the
817 HPV positive samples (Detections of the 21 HPV ge-
notypes were performed in each sample), only 20 cases
were positive (in 6 single infection cases and for add-
itional types in 14 multiple infection cases) in the se-
quencing test but negative in the BMRT HPV PCR
assay. However, among these 20 cases only two were di-
agnosed as CINII-III and the others were diagnosed as
normal, cervicitis and CINI. This result suggests that the
BMRT PCR method could successfully detect HPV in-
fections and identify HPV genotypes with a high degree
of accuracy.
In this study, the results showed that the median rela-
tive levels of HPV-16 DNA do not vary by more than 2-
folds irrespective of the severity of CIN. There is also no
statistical significance of viral loads in samples between
the two CIN groups, as well as between each of the two
CIN groups and the cancer group by Kruskal-Wallis test.
The data indicate that viral load does not correlate with
disease progression within the CIN spectrum. However,
highly significant differences of viral loads were achieved
when comparing the group lacking CIN with the group
comprising of all CIN (p < 0.001) or with the cancer
group (p < 0.001). A significant decrease of viral load in
liquid based cytology samples from cervical carcinoma
patients compared to those from CIN patients was re-
ported by Yoshida et al [27]. However, our quantitative
data showed that the relative number of HPV genomic
copies within a histological entity can vary within the
upper and lower quartile of the box plot (Fig. 1). The
differences are several log-folds when considering the
extreme values of each group. Similar observations were
reported in a recent study in which the variation in
HPV-16 viral load within different histological grades of
cervical neoplasia were evaluated [28]. It is therefore
likely that changes in viral load over time, rather than a
single measurement, might be predictive for disease pro-
gression or clearance [17].
In contrast to HPV-16, viral loads of HPV-18 were less
associated with CINII-III or cancer. This observation may
be due to the different viral activity between HPV-18 and
HPV-16, or a higher proportion of HPV-18 infections in
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patients with glandular lesions that are more difficult to
sample and hence are prone to false-negative results. Our
data suggest that careful attention should be paid to HPV-
18 as the same as to HPV-16, but for a different reason.
Specifically, the possible use of HPV-18 typing to improve
the detection of cytologically occult lesions should be for-
mally evaluated. Extended analyses, accounting for mul-
tiple carcinogenic infections, are necessary to evaluate the
role of viral load for other carcinogenic HPV types.
From an economic point, the BMRT HPV PCR assay
costs less and is faster (less than 2.5 h, including DNA
extraction). Moreover, the real-time PCR assay enables re-
liable quantifications of the target DNA. Our approach
provides a potential for viral load assessment for 21 types
in parallel (not only HPV-16 and HPV-18). Additionally,
the assay will be useful to evaluate the clinical relevance of
viral persistence at the genotype level, monitor disease re-
currence, and examine the effects of widespread vaccin-
ation on prevalent HPV types in the future.
Conclusion
The BMRT assay showed a similar clinical performance
for genotyping compared with the HPV GenoArray test
and seemed to be a good alternative approach for HR-
HPV testing,due to its high level of automation and ability
to quantify HPV - 16, HPV - 18 and other HR-HPV.
Moreover, the BMRT assay could potentially promote pa-
tient management by risk stratification of cytological ab-
normal populations. This new assay could be a useful tool
for both primary screening of cervical cancer and the tri-
age of women with abnormal cytology.
Abbreviations
HPV: Human papillomavirus; NILM: Intraepithelial lesion or malignancy;
BMRT: BioPerfectus Multiplex Real Time; CIN: Cervical intraepithelial neoplasia
grade; RLB: Reverse line blot; LR: Low risk; GAPDH: Glyceraldehyde 3-phosphate
dehydrogenase; UDG: Uracil-DNA-Glycosylase; ASCUS: Atypical squamous cells
of undetermined significance; LSIL: Low-grade squamous intraepithelial lesions;
HSIL: High grade squamous intraepithelial lesions; AUC: Area under the curve.
Competing interests
The present test is the subject of Chinese patent [ZL201110087602.1], and
dependent patent applications worldwide held by Jiangsu Bioperfectus
Technologies Limited company, of which Xu Zhang is sole shareholders,
Rong Zhang, Zhonghua Liu and Xiulin Li are co-inventors.
Authors’ contribution
ZS, RZ and ZL carried out the BioPerfectus multiplex real time, statistical
analysis. and drafted the manuscript. CL, XL, WZ and LY performed the
clinical detection. QR and XZ conceived the study, and participated in its
design and coordination and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
This work was supported by the National Natural Science Foundation of
China (81171580 and 81171581) and the Outstanding Scientific Fund of
Shengjing Hospital.
Received: 8 May 2015 Accepted: 30 October 2015
References
1. Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, et al. Development and
characterization of the cobas human papillomavirus test. J Clin Microbiol.
2013;51:1478–84.
2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.
A review of human carcinogens–Part B: biological agents. Lancet Oncol.
2009;10:321–2.
3. Tabrizi SN, Brotherton JM, Stevens MP, Condon JR, McIntyre P, Smith D, et
al. HPV genotype prevalence in Australian women undergoing routine
cervical screening by cytology status prior to implementation of an HPV
vaccination program. J Clin Virol. 2014;60:250–6.
4. Ong JJ, Read TR, Vodstrcil LA, Walker S, Chen M, Bradshaw CS, et al.
Detection of oral human papillomavirus in HIV-positive men who have sex
with men 3 years after baseline: a follow up cross-sectional study. PLoS
One. 2014;9:e102138.
5. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human
papillomavirus type distribution in 30,848 invasive cervical cancers
worldwide: Variation by geographical region, histological type and year of
publication. Int J Cancer. 2011;128:927–35.
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
et al. Human papillomavirus genotype attribution in invasive cervical cancer:
a retrospective cross-sectional worldwide study. Lancet Oncol.
2010;11:1048–56.
7. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical
intraepithelial neoplasia grade 3 or worse following human papillomavirus
infection: role of persistence. J Natl Cancer Inst. 2010;102:1478–88.
8. Chaturvedi AK, Katki HA, Hildesheim A, Rodriguez AC, Quint W, Schiffman
M, et al. Human papillomavirus infection with multiple types: pattern of
coinfection and risk of cervical disease. J Infect Dis. 2011;203:910–20.
9. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M.
Concurrent infection with multiple human papillomavirus types: pooled
analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers
Prev. 2010;19:503–10.
10. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, et al.
Prevalence and clustering patterns of human papillomavirus genotypes in
multiple infections. Cancer Epidemiol Biomarkers Prev. 2005;14:2439–45.
11. Spinillo A, Dal Bello B, Alberizzi P, Cesari S, Gardella B, Roccio M, et al.
Clustering patterns of human papillomavirus genotypes in multiple
infections. Virus Res. 2009;142:154–9.
12. Mejlhede N, Pedersen BV, Frisch M, Fomsgaard A. Multiple human
papilloma virus types in cervical infections: competition or synergy? APMIS.
2010;118:346–52.
13. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM. Multiple
human papillomavirus infection and high grade cervical intraepithelial
neoplasia among women with cytological diagnosis of atypical squamous
cells of undetermined significance or low grade squamous intraepithelial
lesions. Gynecol Oncol. 2009;113:115–9.
14. Stoler MH, Wright Jr TC, Sharma A, Apple R, Gutekunst K, et al. High-risk
human papillomavirus testing in women with ASC-US cytology: results from
the ATHENA HPV study. Am J Clin Pathol. 2011;135:468–75.
15. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, et al.
Viral load of human papillomavirus and risk of CIN3 or cervical cancer.
Lancet. 2002;360:228–9.
16. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L,
Nobbenhuis MA, et al. Human papillomavirus 16 load in normal and
abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J
Cancer. 2002;98:590–5.
17. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL.
Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-
associated lesions. J Clin Virol. 2006;35:270–7.
18. Sun ZR, Ji YH, Zhou WQ, Zhang SL, Jiang WG, Ruan Q. Characteristics of
HPV prevalence among women in Liaoning province, China. Int J Gynaecol
Obstet. 2010;109:105–109.
19. Hanai R, Caron PR, Wang JC. Human TOP3: a single-copy gene encoding
DNA topoisomerase III. Proc Natl Acad Sci U S A. 1996;93:3653–7.
20. Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, et al. Epidemiologic
characterization of human papillomavirus infection in rural Chaozhou,
eastern Guangdong Province of China. PLoS One. 2012;7:e32149.
21. Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, et al. Prevalence of
human papillomavirus types in women screened by cytology in Germany.
J Med Virol. 2007;79:616–25.
Sun et al. BMC Cancer  (2015) 15:860 Page 10 of 11
22. Wentzensen N, Gravitt PE, Long R, Schiffman M, Dunn ST, Carreon JD, et al.
Human Papillomavirus Load Measured by Linear Array Correlates with
Quantitative PCR in Cervical Cytology Specimens. J Clin Microbiol.
2012;50:1564–70.
23. Marongiu L, Godi A, Parry JV, Beddows S. Human Papillomavirus 16, 18, 31
and 45 viral load, integration and methylation status stratified by cervical
disease stage. BMC Cancer. 2014;14:384.
24. Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, et al.
Evaluation of different techniques for identification of human
papillomavirus types of low prevalence. J Clin Microbiol. 2008;46:1606–13.
25. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus
detection and typing by cycle sequencing, line blotting, and hybrid capture.
J Clin Microbiol. 2000;38:651–5.
26. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-
control study of cervical cancer risk associated with human papillomavirus
infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis.
2004;189:1829–32.
27. Amakura Y, Yoshimura M, Mouri C, Mikage M, Kawahara N, et al. Convenient
TLC-based Identification Test for the Crude Drug “Pogostemoni Herba”.
Yakugaku Zasshi. 2008;128:1833–7.
28. Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, et
al. Variation in human papillomavirus type-16 viral load within different
histological grades of cervical neoplasia. J Med Virol. 2007;79:1366–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sun et al. BMC Cancer  (2015) 15:860 Page 11 of 11
